Halia Therapeutics

Halia Therapeutics is the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex. NLRP3 acts as an essential downstream effector of signals that trigger inflammatory responses and has been implicated in driving the onset and progression of many chronic inflammatory diseases. Activation of NLRP3 triggers the release of the pro-inflammatory cytokines IL-1β IL-18 and induces a lytic cell death process called pyroptosis. These processes lead to chronic inflammation. Persistent activation of the NLRP3 inflammasome is thought to drive the onset and progression of many conditions, including fibrotic, dermatological, and rheumatological diseases. Halia’s therapeutic inhibitor of the NLRP3 inflammasome prevents the formation and promotes its disassembly once formed, thereby inhibiting the production and release of IL-1β and IL-18.